Evidence map›Paper›PMID 41704442›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2026

Generation and characterization of a HEK293 cell line optimized for recombinant adeno-associated virus production.

Mélissa Vona, Iris Bodenmann, Marc-Antoine Perrenoud, Rachel Buchs, Pelin Kolcak Yasli, Luca Nanni, Romain Daveau, Alexandre Félix, Jens Stolte, Ann-Kristin Hov and 6 more

Abstract read
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mélissa VonaNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Iris BodenmannNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Marc-Antoine PerrenoudNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Rachel BuchsNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Pelin Kolcak YasliNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Luca NanniNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Romain DaveauNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Alexandre FélixNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Jens StolteNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Ann-Kristin HovNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Bertrand CholletNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Thierry SchuepbachNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Déborah LeyNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Efrain GuzmanNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Igor FischNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.
Nicolas MermodNewBiologix SA, Route de la Corniche 6-8, 1066 Epalinges, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HEK293 is a preferred cellular platform to produce viral vectors including adeno-associated viruses (AAV). However, HEK293 cells were shown to be genomically unstable and many HEK293 cell lines having distinct genotypes and phenotypes have been reported. Here we generated a stable clonal cell line specifically selected for the optimal production of recombinant AAV (rAAV) by the triple plasmid transfection method. Initially over two thousand single cell clones were isolated from a HEK293 polyclonal cell line and evaluated for their growth profile in suspension, doubling time, ability to recover freeze-thaw cycles and transfection efficacy. A selection of clones that met these specific criteria were then screened for their ability to produce high rAAV titers by triple plasmid transfection, yielding one high-performing clone named NBX1P01. This clone was genomically characterized using optical genome mapping and whole genome sequencing and further evaluated for rAAV production capacity across different serotypes and genes of interest (GOI). NBX1P01 was shown to be genomically stable over 55 population doubling levels (PDL), highly transfectable and able to produce rAAV titers similar or higher than those produced by a commercially available HEK293 cell line using the same culture, transfection, harvest and quantification protocol. The ratio of full-to-empty rAAV particles produced by NBX1P01 was two-fold higher than those of the commercial cell line. Long-read sequencing of the encapsidated DNA from the NBX1P01-produced rAAV indicated high levels of genome integrity with minimal levels of contaminants. These results demonstrated the versatility of NBX1P01 cells and their ability to produce high-quality rAAV vectors.

Indexed as

Adeno-associated viral vectorsCell line developmentHuman cell linesViral vector production

Identifiers

PMID41704442
PMCPMC12907237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.